This study is looking at how a special high-CBD product (a type of cannabis compound) might help people with gynecologic pain caused by endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID). Researchers want to understand how the product works in the body and if it can reduce pain. You would receive either the high-CBD product or a placebo (an inactive substance) for one week. The study will measure levels of CBD and its related compounds, as well as markers of inflammation and a natural body chemical called anandamide, to see the product's effects. This study is for women aged 21 and older who have one of these pain conditions and stable medication routines. The current recruitment status is unclear.

Study design

This is a double-blind, placebo-controlled study, meaning neither you nor the researchers will know if you're receiving the high-CBD product or placebo. About 60 participants are planned.

What's involved

You would have three visits to McLean Hospital over about one week. These visits include clinical interviews, medical screenings, urine and blood samples, questionnaires, and sensory tests. You would also self-administer the study product and track its use for one week.

Compensation

Not stated in the trial record.

Follow-up

The primary measurements for this study are taken at baseline and after 7 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.